Orally Administered Activated Charcoal as a Medical Countermeasure for Acute Radiation Syndrome in Rats

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10045/114287
Registro completo de metadatos
Registro completo de metadatos
Campo DCValorIdioma
dc.contributorMateriales Avanzadoses_ES
dc.contributor.authorSnezhkova, Elisaveta-
dc.contributor.authorRodionova, Natalia-
dc.contributor.authorBilko, Dennis-
dc.contributor.authorSilvestre-Albero, Joaquín-
dc.contributor.authorSydorenko, Alexey-
dc.contributor.authorYurchenko, Olga-
dc.contributor.authorPakharenko, Marharyta-
dc.contributor.authorAlavijeh, Mo-
dc.contributor.authorBardakhivska, Kvitoslava-
dc.contributor.authorRiabchenko, Natalia-
dc.contributor.authorNikolaev, Vladimir-
dc.contributor.otherUniversidad de Alicante. Departamento de Química Inorgánicaes_ES
dc.contributor.otherUniversidad de Alicante. Instituto Universitario de Materialeses_ES
dc.date.accessioned2021-04-20T16:43:47Z-
dc.date.available2021-04-20T16:43:47Z-
dc.date.issued2021-04-02-
dc.identifier.citationSnezhkova E, Rodionova N, Bilko D, Silvestre-Albero J, Sydorenko A, Yurchenko O, Pakharenko M, Alavijeh M, Bardakhivska K, Riabchenko N, Nikolaev V. Orally Administered Activated Charcoal as a Medical Countermeasure for Acute Radiation Syndrome in Rats. Applied Sciences. 2021; 11(7):3174. https://doi.org/10.3390/app11073174es_ES
dc.identifier.issn2076-3417-
dc.identifier.urihttp://hdl.handle.net/10045/114287-
dc.description.abstractActivated charcoal (AC) can be taken orally as enterosorbent for treatment of pathological states related to exogenous and endogenous intoxications. Synthesized granulated AC with a highly developed active surface (SBET ~2700 m2/g) was used as a medical countermeasure (MCM) to acute radiation sickness (ARS) in rats after total body X-ray irradiation. AC demonstrates positive results in ARS treatment, as expressed in, (i) a decrease in body weight loss, (ii) a protection of bone marrow (BM) cells colony formation capacity, (iii) a reduction of BM chromosomal aberrations and small intestine and spleen tissue damage, (iv) an amelioration of white blood cell count, and (v) a mitigation of superoxide ion generation rate in the liver. AC oral prescription seems to be perspective modality of ARS treatment.es_ES
dc.description.sponsorshipThis research was funded by H2020-MSCA-RISE-2016 project, grant number 734641 acronym NanoMed.es_ES
dc.languageenges_ES
dc.publisherMDPIes_ES
dc.rights© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).es_ES
dc.subjectActivated charcoales_ES
dc.subjectEnterosorbentes_ES
dc.subjectAcute radiation sicknesses_ES
dc.subjectRatses_ES
dc.subject.otherQuímica Inorgánicaes_ES
dc.titleOrally Administered Activated Charcoal as a Medical Countermeasure for Acute Radiation Syndrome in Ratses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.peerreviewedsies_ES
dc.identifier.doi10.3390/app11073174-
dc.relation.publisherversionhttps://doi.org/10.3390/app11073174es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/734641es_ES
Aparece en las colecciones:INV - LMA - Artículos de Revistas
Investigaciones financiadas por la UE

Archivos en este ítem:
Archivos en este ítem:
Archivo Descripción TamañoFormato 
ThumbnailSnezhkova_etal_2021_ApplSci.pdf3,27 MBAdobe PDFAbrir Vista previa


Este ítem está licenciado bajo Licencia Creative Commons Creative Commons